- Our news -
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
perception neuroscience presents results from phase 2b trial of pcn-101 at the ascp 2023 annual meeting
Perception Neurosciences Announces Additional Analyses from the Phase 2a Trial of PCN-101 (R-ketamine) at the ASCP 2023 Annual Meeting
PERCEPTION NEUROSCIENCE ANNOUNCES FIRST DOSING OF SUBJECTS IN THE PCN-101 IV-TO-SUBCUTANEOUS BRIDGING STUDY
Perception Neuroscience Announces Appointments of Maju Mathews, MD, as Chief Medical Officer and Cedric Burg, PhD as Senior Vice President, Clinical Operations
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders
Perception Neuroscience announced positive data from its first Phase 1 clinical study demonstrating the safety and tolerability of PCN-101 (R-ketamine).
Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience
ATAI Life Sciences acquires majority stake in Perception Neuroscience to develop arketamine therapy for neuropsychiatric diseases
- Other news -
Are Investors Ready To Change Their Minds About Psychedelic Drugs?
Yet as Dr. Terence Kelly, CEO of Perception Neuroscience, noted, the regulatory authorities are very familiar with psychedelic substances and tend to be cooperative regarding their research.